Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias. - Zhang W; Li L; Muftuoglu M; Basyal M; Togashi N; Iwanaga K; Tanzawa F; Numata M; Bixby DL; Erba HP; Podoltsev N; Schiller GJ; et al. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025)